| Literature DB >> 28768908 |
Rosanne Rouf1, Elena Gallo MacFarlane2, Eiki Takimoto1, Rahul Chaudhary1, Varun Nagpal2, Peter P Rainer1, Jay G Bindman2, Elizabeth E Gerber2, Djahida Bedja1, Christopher Schiefer1, Karen L Miller1, Guangshuo Zhu1, Loretha Myers2, Nuria Amat-Alarcon1, Dong I Lee1, Norimichi Koitabashi1, Daniel P Judge1, David A Kass1, Harry C Dietz2,3.
Abstract
Among children with the most severe presentation of Marfan syndrome (MFS), an inherited disorder of connective tissue caused by a deficiency of extracellular fibrillin-1, heart failure is the leading cause of death. Here, we show that, while MFS mice (Fbn1C1039G/+ mice) typically have normal cardiac function, pressure overload (PO) induces an acute and severe dilated cardiomyopathy in association with fibrosis and myocyte enlargement. Failing MFS hearts show high expression of TGF-β ligands, with increased TGF-β signaling in both nonmyocytes and myocytes; pathologic ERK activation is restricted to the nonmyocyte compartment. Informatively, TGF-β, angiotensin II type 1 receptor (AT1R), or ERK antagonism (with neutralizing antibody, losartan, or MEK inhibitor, respectively) prevents load-induced cardiac decompensation in MFS mice, despite persistent PO. In situ analyses revealed an unanticipated axis of activation in nonmyocytes, with AT1R-dependent ERK activation driving TGF-β ligand expression that culminates in both autocrine and paracrine overdrive of TGF-β signaling. The full compensation seen in wild-type mice exposed to mild PO correlates with enhanced deposition of extracellular fibrillin-1. Taken together, these data suggest that fibrillin-1 contributes to cardiac reserve in the face of hemodynamic stress, critically implicate nonmyocytes in disease pathogenesis, and validate ERK as a therapeutic target in MFS-related cardiac decompensation.Entities:
Keywords: Cardiology; Genetics
Year: 2017 PMID: 28768908 PMCID: PMC5543913 DOI: 10.1172/jci.insight.91588
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708